Opened 79 days ago

Closes 30 November 2021

Trial Aim Description

Two new drug trials for people with Huntington’s disease, called PRECISION-HD1 and PRECISION-HD2. Each study tests a separate Huntingtin-lowering (also known as gene silencing) agent. They are run by a company called Wave Life Sciences based in Massachusetts, USA.

Trial Eligibility Requirements

Participants must be between the ages of 25-65, have early stage Huntington’s disease, and meet additional criteria. The studies involve lumbar punctures, MRI scans, assessments and questionnaires.

Interested? Enquire today

Principal Investigator: Dr Carolyn Orr

View more trials